3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

医学 奥沙利铂 佐剂 内科学 结直肠癌 辅助治疗 肿瘤科 癌症
作者
Timothy Iveson,Rachel Kerr,Mark Saunders,Jim Cassidy,Niels Henrik Holländer,Josep Tabernero,Andrew Haydon,Bengt Glimelius,Andrea Harkin,Karen Allan,John McQueen,Claire Scudder,Kathleen Boyd,Andrew Briggs,Ashita Waterston,Louise Medley,Charles B. Wilson,Richard Ellis,Sharadah Essapen,A.S. Dhadda
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (4): 562-578 被引量:185
标识
DOI:10.1016/s1470-2045(18)30093-7
摘要

Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Methods: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. Findings: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1–78·2) for the 3 month group and 77·1% (75·6–78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909–1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). Interpretation: In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. Funding: Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
凝神揽玥完成签到,获得积分10
刚刚
niiiiii完成签到,获得积分10
1秒前
123654完成签到 ,获得积分0
1秒前
1秒前
小红完成签到,获得积分10
1秒前
莫大完成签到 ,获得积分10
3秒前
大金鱼完成签到 ,获得积分10
3秒前
WXJ完成签到,获得积分10
4秒前
4秒前
ypp完成签到,获得积分10
4秒前
苹果安蕾完成签到,获得积分10
4秒前
旋风0127发布了新的文献求助10
5秒前
FashionBoy的应助被闻疏采纳,获得10
6秒前
Awt完成签到,获得积分20
6秒前
阿良完成签到 ,获得积分10
7秒前
科研通AI6.4的应助被香蕉大树采纳,获得10
7秒前
杨茜然完成签到 ,获得积分10
8秒前
chenbinwang完成签到 ,获得积分20
10秒前
DYZ完成签到,获得积分10
10秒前
Ll完成签到,获得积分10
10秒前
健壮鸡翅完成签到 ,获得积分10
10秒前
高刘田完成签到 ,获得积分10
10秒前
Cheng9nine完成签到,获得积分10
11秒前
123完成签到,获得积分10
11秒前
予七完成签到 ,获得积分10
12秒前
liuguohua126完成签到,获得积分10
12秒前
逍遥小书生完成签到 ,获得积分10
13秒前
柠檬水要加冰完成签到,获得积分10
13秒前
文静如容完成签到 ,获得积分10
14秒前
隐形曼青的应助被苹果安蕾采纳,获得10
14秒前
FashionBoy的应助被王首斌采纳,获得10
15秒前
细心沛山完成签到,获得积分10
16秒前
xixi2517完成签到,获得积分10
18秒前
lihn完成签到,获得积分10
19秒前
bz完成签到,获得积分10
20秒前
秀丽天川完成签到,获得积分10
22秒前
MichaelQiang的应助被中科路2020采纳,获得60
23秒前
23秒前
温柔晓筠完成签到,获得积分10
26秒前
You完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185593
求助须知:如何正确求助?哪些是违规求助? 9574339
关于积分的说明 21835371
捐赠科研通 7783410
什么是DOI,文献DOI怎么找? 3434626
关于科研通互助平台的介绍 2558985
邀请新用户注册赠送积分活动 2481374